Bill Taranto

in the GLP-1 space around those impacts of the world that you can go directly to the patient.

I think that's going to change.

So around patient access support, how does the care delivery infrastructure change?

How do things like, like that literally drug, how do you go more direct to the patient?

Are there ways for us to,

potentially bypass the traditional chain, whether it's, you know, PBMs or however, you know, we get things out there to, you know, more direct to the patient.

Has the patient have more control over their medicines?

You know, we have another company called, that we did with Glenn as well, Tolman called Transparent that helps you identify the right physician for the right product.

You know, if you're getting surgery, you know, who's the right physician for you in the right area for the right price.

So transparency.

I think it will be big.

Value-based care, post sort of market patient support, all these type of areas aren't going anywhere.

So the way we've structured those four quadrants, it's funny, even though we've been investing in the last five or six years, those are still the future of where we think healthcare is going.

But as you said, AI is going to change the way we think about those investments.

New technologies will come that we don't know about yet, but we've got to be prepared to think about, you know, quantum computing.

How's that going to change?

We think it's going to have a big impact on supply chain logistics.

Will it have an impact elsewhere?

So all these technologies continue to evolve and grow.

And the whole idea for us is to keep looking at them, keep trying to predict.